Drugs interactions for Trodelvy®

  • 48 Major drug interactions (including ingredients like Adenine, Amitriptyline, Asciminib)
  • 27 Moderate drug interactions (including ingredients like Articaine, Benzocaine, Benzyl alcohol)
  • 158 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
233 interactions for Trodelvy®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Trodelvy®.
Adenine
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Adenine.
Amitriptyline
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Amitriptyline.
Asciminib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Asciminib.
Atazanavir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Atazanavir.
Carbamazepine
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Carbamazepine.
Dabrafenib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dabrafenib.
Dacomitinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dacomitinib.
Dasabuvir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dasabuvir.
Defactinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Defactinib.
Deferasirox
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Deferasirox.
Desogestrel
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Desogestrel.
Efavirenz
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Efavirenz.
Eltrombopag
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Eltrombopag.
Enasidenib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Enasidenib.
Encorafenib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Encorafenib.
Erlotinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Erlotinib.
Ethinylestradiol
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Ethinylestradiol.
Flurbiprofen
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Flurbiprofen.
Fostamatinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Fostamatinib.
Gemfibrozil
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Gemfibrozil.
Glecaprevir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Glecaprevir.
Indinavir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Indinavir.
Indomethacin
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Indomethacin.
Ketoconazole
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Ketoconazole.
Lamotrigine
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Lamotrigine.
Mitapivat
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Mitapivat.
Nelfinavir
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Nelfinavir.
Nilotinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Nilotinib.
Ombitasvir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Ombitasvir.
Paritaprevir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Paritaprevir.
Pazopanib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Pazopanib.
Pexidartinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Pexidartinib.
Phenobarbital
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Phenobarbital.
Phenytoin
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Phenytoin.
Pibrentasvir
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Pibrentasvir.
Primidone
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Primidone.
Probenecid
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Probenecid.
Propofol
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Propofol.
Quizartinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Quizartinib.
Regorafenib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Regorafenib.
Repotrectinib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Repotrectinib.
Rifampin
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Rifampicin.
Ritonavir
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Ritonavir.
Sorafenib
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Sorafenib.
Testosterone propionate
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Testosterone propionate.
Tipranavir
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Tipranavir.
Valproic acid
The serum concentration of Sacituzumab govitecan can be increased when it is combined with Valproic acid.
Zidovudine
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Zidovudine.
Articaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Articaine.
Benzocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Benzocaine.
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Benzyl alcohol.
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Bupivacaine.
Butamben
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Butamben.
Capsaicin
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Capsaicin.
Chloroprocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Chloroprocaine.
Cinchocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Cinchocaine.
Cocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Cocaine.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sacituzumab govitecan.
Diphenhydramine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Diphenhydramine.
Dyclonine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Dyclonine.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sacituzumab govitecan.
Etrasimod
The risk or severity of immunosuppression can be increased when Sacituzumab govitecan is combined with Etrasimod.
Lidocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Lidocaine.
Meloxicam
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Meloxicam.
Mepivacaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Mepivacaine.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sacituzumab govitecan.
Oxybuprocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Oxybuprocaine.
Phenol
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Phenol.
Pozelimab
The serum concentration of Pozelimab can be decreased when it is combined with Sacituzumab govitecan.
Pramocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Pramocaine.
Prilocaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Prilocaine.
Procaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Procaine.
Proparacaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Proparacaine.
Ropivacaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Ropivacaine.
Tetracaine
The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Tetracaine.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Sacituzumab govitecan.
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Sacituzumab govitecan.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Sacituzumab govitecan.
Amivantamab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Amivantamab.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Sacituzumab govitecan.
Ansuvimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Ansuvimab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Sacituzumab govitecan.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Sacituzumab govitecan.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sacituzumab govitecan.
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Sacituzumab govitecan.
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Sacituzumab govitecan.
Atoltivimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Atoltivimab.
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Sacituzumab govitecan.
Axatilimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Axatilimab.
Bamlanivimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Bamlanivimab.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Sacituzumab govitecan.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Sacituzumab govitecan.
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Sacituzumab govitecan.
Bevacizumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.
Bezlotoxumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Bezlotoxumab.
Bimekizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Bimekizumab.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sacituzumab govitecan.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sacituzumab govitecan.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Sacituzumab govitecan.
Brolucizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Brolucizumab.
Burosumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Burosumab.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Sacituzumab govitecan.
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sacituzumab govitecan.
Cemiplimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Cemiplimab.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Sacituzumab govitecan.
Cetuximab
The risk or severity of adverse effects can be increased when Cetuximab is combined with Sacituzumab govitecan.
Cilgavimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Cilgavimab.
Clesrovimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Clesrovimab.
Conjugated estrogens
Conjugated estrogens may increase the thrombogenic activities of Sacituzumab govitecan.
Cosibelimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Cosibelimab.
Crovalimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Crovalimab.
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Sacituzumab govitecan.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Sacituzumab govitecan.
Digoxin Immune Fab (Ovine)
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sacituzumab govitecan.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sacituzumab govitecan.
Donanemab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Donanemab.
Dostarlimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Dostarlimab.
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sacituzumab govitecan.
Dupilumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Sacituzumab govitecan.
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Sacituzumab govitecan.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Sacituzumab govitecan.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Sacituzumab govitecan.
Eflapegrastim
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Eflapegrastim.
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Sacituzumab govitecan.
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Sacituzumab govitecan.
Emapalumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Emapalumab.
Emicizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Emicizumab.
Eptinezumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Eptinezumab.
Erenumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Erenumab.
Esterified estrogens
Esterified estrogens may increase the thrombogenic activities of Sacituzumab govitecan.
Estetrol
Estetrol may increase the thrombogenic activities of Sacituzumab govitecan.
Estradiol
Estradiol may increase the thrombogenic activities of Sacituzumab govitecan.
Estradiol acetate
Estradiol acetate may increase the thrombogenic activities of Sacituzumab govitecan.
Estradiol cypionate
Estradiol cypionate may increase the thrombogenic activities of Sacituzumab govitecan.
Estradiol valerate
Estradiol valerate may increase the thrombogenic activities of Sacituzumab govitecan.
Estriol
Estriol may increase the thrombogenic activities of Sacituzumab govitecan.
Estrone sulfate
Estrone sulfate may increase the thrombogenic activities of Sacituzumab govitecan.
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Sacituzumab govitecan.
Fanolesomab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Fanolesomab.
Fremanezumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Fremanezumab.
Galcanezumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Galcanezumab.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan.
Glofitamab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Glofitamab.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Sacituzumab govitecan.
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Sacituzumab govitecan.
Hepatitis B immune globulin
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sacituzumab govitecan.
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Human cytomegalovirus immune globulin.
Human immunoglobulin G
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sacituzumab govitecan.
Human Rho(D) immune globulin
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Sacituzumab govitecan.
Human varicella-zoster immune globulin
The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Sacituzumab govitecan.
Ibalizumab
The risk or severity of adverse effects can be increased when Ibalizumab is combined with Sacituzumab govitecan.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan.
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Sacituzumab govitecan.
Inebilizumab
The risk or severity of adverse effects can be increased when Inebilizumab is combined with Sacituzumab govitecan.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Sacituzumab govitecan.
Inotuzumab ozogamicin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sacituzumab govitecan.
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sacituzumab govitecan.
Isatuximab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Isatuximab.
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Sacituzumab govitecan.
Lanadelumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Lanadelumab.
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Sacituzumab govitecan.
Lecanemab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Lecanemab.
Linvoseltamab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Linvoseltamab.
Loncastuximab tesirine
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Loncastuximab tesirine.
Maftivimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Maftivimab.
Margetuximab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Margetuximab.
Marstacimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Marstacimab.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Sacituzumab govitecan.
Mirvetuximab soravtansine
The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Sacituzumab govitecan.
Mogamulizumab
The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Sacituzumab govitecan.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Mosunetuzumab.
Natalizumab
The risk or severity of adverse effects can be increased when Natalizumab is combined with Sacituzumab govitecan.
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Sacituzumab govitecan.
Nemolizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Nemolizumab.
Nipocalimab
The serum concentration of Sacituzumab govitecan can be decreased when it is combined with Nipocalimab.
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Sacituzumab govitecan.
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Sacituzumab govitecan.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sacituzumab govitecan.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Sacituzumab govitecan.
Odesivimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Odesivimab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sacituzumab govitecan.
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Sacituzumab govitecan.
Omalizumab
The risk or severity of adverse effects can be increased when Omalizumab is combined with Sacituzumab govitecan.
Palivizumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Sacituzumab govitecan.
Panitumumab
The risk or severity of adverse effects can be increased when Panitumumab is combined with Sacituzumab govitecan.
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Sacituzumab govitecan.
Penpulimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Penpulimab.
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Sacituzumab govitecan.
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sacituzumab govitecan.
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Sacituzumab govitecan.
Ranibizumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Sacituzumab govitecan.
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Sacituzumab govitecan.
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Sacituzumab govitecan.
Relatlimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Relatlimab.
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Sacituzumab govitecan.
Risankizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Sacituzumab govitecan.
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Sacituzumab govitecan.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Rozanolixizumab.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Sacituzumab govitecan.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Sacituzumab govitecan.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Sacituzumab govitecan.
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Sacituzumab govitecan.
Sotrovimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Sotrovimab.
Spesolimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Spesolimab.
Sutimlimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Sutimlimab.
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Sacituzumab govitecan.
Synthetic Conjugated Estrogens, B
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sacituzumab govitecan.
Tafasitamab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tafasitamab.
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Telisotuzumab vedotin.
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Sacituzumab govitecan.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sacituzumab govitecan.
Tetanus immune globulin, human
The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Sacituzumab govitecan.
Tezepelumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tezepelumab.
Tildrakizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tildrakizumab.
Tislelizumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tislelizumab.
Tisotumab vedotin
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tisotumab vedotin.
Tixagevimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tixagevimab.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Sacituzumab govitecan.
Toripalimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Toripalimab.
Tralokinumab
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Sacituzumab govitecan.
Trastuzumab
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sacituzumab govitecan.
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Trastuzumab deruxtecan.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Sacituzumab govitecan.
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Sacituzumab govitecan.
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Sacituzumab govitecan.
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Sacituzumab govitecan.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Sacituzumab govitecan.
Vilobelimab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Vilobelimab.
Zanidatamab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Zanidatamab.
Zenocutuzumab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Zenocutuzumab.
Zolbetuximab
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Zolbetuximab.